Treace Medical Concepts Inc
$ 4.30
-2.93%
17 Jul - close price
- Market Cap 278,954,000 USD
- Current Price $ 4.30
- High / Low $ 4.39 / 4.05
- Stock P/E N/A
- Book Value 1.19
- EPS -0.93
- Next Earning Report 2026-08-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.18 %
- ROE -0.67 %
- 52 Week High 7.78
- 52 Week Low 1.17
About
Treace Medical Concepts, Inc., an orthopedic medical device company, is dedicated to the design, manufacture, and marketing of biological devices and / or solutions for foot and ankle surgeons in the United States. The company is headquartered in Ponte Vedra Beach, Florida.
Analyst Target Price
$4.67
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-08 | 2026-02-27 | 2025-11-06 | 2025-08-07 | 2025-05-08 | 2025-02-27 | 2024-11-05 | 2024-08-06 | 2024-05-07 | 2024-02-27 | 2023-11-09 | 2023-08-08 |
| Reported EPS | -0.28 | -0.0783 | -0.22 | -0.28 | -0.25 | -0.0016 | -0.25 | -0.28 | -0.28 | -0.1 | -0.28 | -0.2 |
| Estimated EPS | -0.31 | -0.1521 | -0.27 | -0.29 | -0.3 | -0.0427 | -0.26 | -0.28 | -0.31 | -0.09 | -0.26 | -0.23 |
| Surprise | 0.03 | 0.0738 | 0.05 | 0.01 | 0.05 | 0.0411 | 0.01 | 0 | 0.03 | -0.01 | -0.02 | 0.03 |
| Surprise Percentage | 9.6774% | 48.5207% | 18.5185% | 3.4483% | 16.6667% | 96.2529% | 3.8462% | 0% | 9.6774% | -11.1111% | -7.6923% | 13.0435% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-06 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.3 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TMCI
2026-07-17 08:11:19
Treace Medical Concepts (NASDAQ: TMCI) has received a "Reduce" consensus rating from seven brokerages, with an average 12-month price target of $4.97. Despite analysts' cautious outlook, the company exceeded recent quarterly earnings and revenue estimates. Notably, insider and institutional buying has been strong, with the CEO purchasing shares and hedge funds owning a significant portion of the stock.
2026-07-16 17:09:58
Truist Financial has increased its price target for Treace Medical Concepts (NASDAQ:TMCI) to $4.00, up from $2.00, while maintaining a "hold" rating, suggesting an 11.6% potential downside. The company recently reported better-than-expected quarterly results with an EPS of -$0.28 and revenue of $47.2 million, leading to a 2.8% rise in its stock price. Insider trading shows CEO John T. Treace acquired 61,750 shares, and institutional investors collectively own 84.08% of the company's stock.
2026-07-15 13:45:17
Treace Medical Concepts, Inc. (NASDAQ:TMCI) experienced a significant 46.6% decline in short interest in June, bringing the total to 1.75 million shares or about 3.5% of its outstanding shares. Despite weak fundamentals, including a negative net margin and anticipated full-year loss, insider buying has been notable, with CEO John T. Treace acquiring additional shares and institutional investors adjusting their positions. Analysts currently hold a consensus "Reduce" rating for the stock with a price target of $4.77.
2026-07-14 08:12:39
Johnson Fistel, PLLP is investigating potential breaches of fiduciary duty by officers and directors of Treace Medical Concepts, Inc. (TMCI) on behalf of long-term shareholders who held shares continuously since before May 8, 2023. The investigation focuses on alleged false and misleading statements regarding competition impacting the demand for Treace's primary product, the Lapiplasty, and the company's need to accelerate alternative product offerings. Shareholders may have standing to seek corporate governance reforms and the return of funds to the company.
2026-07-13 14:10:25
Johnson Fistel, PLLP is investigating Treace Medical Concepts, Inc. on behalf of long-term shareholders for alleged breaches of fiduciary duty by its officers and directors. The investigation stems from allegations that Treace made false or misleading statements regarding its business, specifically concerning competition and revenue declines for its main product. Shareholders who held shares before May 8, 2023, may be eligible for corporate governance reforms and financial recovery.
2026-07-13 09:49:00
Johnson Fistel, PLLP is investigating potential breach of fiduciary duty claims against officers and directors of Treace Medical Concepts, Inc. (TMCI) on behalf of long-term shareholders who held shares continuously before May 8, 2023. The investigation stems from allegations in a previously filed securities class action that claimed the company made materially false or misleading statements regarding competition and declining revenue impacting its primary product. Shareholders could seek corporate governance reforms and financial returns to the company.
